---
provider: falcon
model: Edison Scientific Literature
cached: false
start_time: '2025-12-27T10:39:14.983869'
end_time: '2025-12-27T10:48:23.413484'
duration_seconds: 548.43
template_file: templates/gene_research_go_focused.md
template_variables:
  organism: human
  gene_id: KCTD16
  gene_symbol: KCTD16
  uniprot_accession: Q68DU8
  protein_description: 'RecName: Full=BTB/POZ domain-containing protein KCTD16; AltName:
    Full=Potassium channel tetramerization domain-containing protein 16;'
  gene_info: Name=KCTD16; Synonyms=KIAA1317;
  organism_full: Homo sapiens (Human).
  protein_family: Not specified in UniProt
  protein_domains: BTB/POZ_dom. (IPR000210); H1_KCTD16. (IPR049903); SKP1/BTB/POZ_sf.
    (IPR011333); T1-type_BTB. (IPR003131); BTB_2 (PF02214)
provider_config:
  timeout: 600
  max_retries: 3
  parameters:
    allowed_domains: []
    temperature: 0.1
citation_count: 39
---

## Question

# Gene Research for Functional Annotation

## ⚠️ CRITICAL: Gene/Protein Identification Context

**BEFORE YOU BEGIN RESEARCH:** You MUST verify you are researching the CORRECT gene/protein. Gene symbols can be ambiguous, especially for less well-characterized genes from non-model organisms.

### Target Gene/Protein Identity (from UniProt):
- **UniProt Accession:** Q68DU8
- **Protein Description:** RecName: Full=BTB/POZ domain-containing protein KCTD16; AltName: Full=Potassium channel tetramerization domain-containing protein 16;
- **Gene Information:** Name=KCTD16; Synonyms=KIAA1317;
- **Organism (full):** Homo sapiens (Human).
- **Protein Family:** Not specified in UniProt
- **Key Domains:** BTB/POZ_dom. (IPR000210); H1_KCTD16. (IPR049903); SKP1/BTB/POZ_sf. (IPR011333); T1-type_BTB. (IPR003131); BTB_2 (PF02214)

### MANDATORY VERIFICATION STEPS:

1. **Check if the gene symbol "KCTD16" matches the protein description above**
2. **Verify the organism is correct:** Homo sapiens (Human).
3. **Check if protein family/domains align with what you find in literature**
4. **If you find literature for a DIFFERENT gene with the same or similar symbol, STOP**

### If Gene Symbol is Ambiguous or You Cannot Find Relevant Literature:

**DO NOT PROCEED WITH RESEARCH ON A DIFFERENT GENE.** Instead:
- State clearly: "The gene symbol 'KCTD16' is ambiguous or literature is limited for this specific protein"
- Explain what you found (e.g., "Found extensive literature on a different gene with the same symbol in a different organism")
- Describe the protein based ONLY on the UniProt information provided above
- Suggest that the protein function can be inferred from domain/family information

### Research Target:

Please provide a comprehensive research report on the gene **KCTD16** (gene ID: KCTD16, UniProt: Q68DU8) in human.

The research report should be a detailed narrative explaining the function, biological processes, and localization of the gene product. Citations should be given for all claims.

You should prioritize authoritative reviews and primary scientific literature when conducting research. You can supplement
this with annotations you find in gene/protein databases, but these can be outdated or inaccurate.

We are specifically interested in the primary function of the gene - for enzymes, what reaction is catalyzed, and what is the substrate specificity? For transporters, what is the substrate? For structural proteins or adapters, what is the broader structural role? For signaling molecules, what is the role in the pathway.

We are interested in where in or outside the cell the gene product carries out its function.

We are also interested in the signaling or biochemical pathways in which the gene functions. We are less interested in broad pleiotropic effects, except where these elucidate the precise role.

Include evidence where possible. We are interested in both experimental evidence as well as inference from structure, evolution, or bioinformatic analysis. Precise studies should be prioritized over high-throughput, where available.

## Output

Question: You are an expert researcher providing comprehensive, well-cited information.

Provide detailed information focusing on:
1. Key concepts and definitions with current understanding
2. Recent developments and latest research (prioritize 2023-2024 sources)
3. Current applications and real-world implementations
4. Expert opinions and analysis from authoritative sources
5. Relevant statistics and data from recent studies

Format as a comprehensive research report with proper citations. Include URLs and publication dates where available.
Always prioritize recent, authoritative sources and provide specific citations for all major claims.

# Gene Research for Functional Annotation

## ⚠️ CRITICAL: Gene/Protein Identification Context

**BEFORE YOU BEGIN RESEARCH:** You MUST verify you are researching the CORRECT gene/protein. Gene symbols can be ambiguous, especially for less well-characterized genes from non-model organisms.

### Target Gene/Protein Identity (from UniProt):
- **UniProt Accession:** Q68DU8
- **Protein Description:** RecName: Full=BTB/POZ domain-containing protein KCTD16; AltName: Full=Potassium channel tetramerization domain-containing protein 16;
- **Gene Information:** Name=KCTD16; Synonyms=KIAA1317;
- **Organism (full):** Homo sapiens (Human).
- **Protein Family:** Not specified in UniProt
- **Key Domains:** BTB/POZ_dom. (IPR000210); H1_KCTD16. (IPR049903); SKP1/BTB/POZ_sf. (IPR011333); T1-type_BTB. (IPR003131); BTB_2 (PF02214)

### MANDATORY VERIFICATION STEPS:

1. **Check if the gene symbol "KCTD16" matches the protein description above**
2. **Verify the organism is correct:** Homo sapiens (Human).
3. **Check if protein family/domains align with what you find in literature**
4. **If you find literature for a DIFFERENT gene with the same or similar symbol, STOP**

### If Gene Symbol is Ambiguous or You Cannot Find Relevant Literature:

**DO NOT PROCEED WITH RESEARCH ON A DIFFERENT GENE.** Instead:
- State clearly: "The gene symbol 'KCTD16' is ambiguous or literature is limited for this specific protein"
- Explain what you found (e.g., "Found extensive literature on a different gene with the same symbol in a different organism")
- Describe the protein based ONLY on the UniProt information provided above
- Suggest that the protein function can be inferred from domain/family information

### Research Target:

Please provide a comprehensive research report on the gene **KCTD16** (gene ID: KCTD16, UniProt: Q68DU8) in human.

The research report should be a detailed narrative explaining the function, biological processes, and localization of the gene product. Citations should be given for all claims.

You should prioritize authoritative reviews and primary scientific literature when conducting research. You can supplement
this with annotations you find in gene/protein databases, but these can be outdated or inaccurate.

We are specifically interested in the primary function of the gene - for enzymes, what reaction is catalyzed, and what is the substrate specificity? For transporters, what is the substrate? For structural proteins or adapters, what is the broader structural role? For signaling molecules, what is the role in the pathway.

We are interested in where in or outside the cell the gene product carries out its function.

We are also interested in the signaling or biochemical pathways in which the gene functions. We are less interested in broad pleiotropic effects, except where these elucidate the precise role.

Include evidence where possible. We are interested in both experimental evidence as well as inference from structure, evolution, or bioinformatic analysis. Precise studies should be prioritized over high-throughput, where available.

Plan
- Verified identity and domains; collected and evaluated recent and foundational sources; synthesized mechanistic function, interactions, signaling context, localization, and clinical relevance; compiled quantitative/statistical data and built an evidence table artifact; composed the final report with citations.

Comprehensive research report: human KCTD16 (UniProt Q68DU8)

1) Key concepts and definitions with current understanding
- Identity, family, domains, organism verification: KCTD16 (gene symbol KCTD16, also known as KIAA1317) is a human potassium channel tetramerization domain-containing protein that belongs to the KCTD family. It contains an N‑terminal BTB/POZ (T1) oligomerization domain and C‑terminal homology regions (H1, and in some members H2). Structural work using human protein fragments confirms that the BTB/T1 forms an open pentamer and binds the distal cytoplasmic tail of the GABAB2 subunit, verifying both the gene symbol and human organism context specified (PDB 6OCP; PNAS 2019). The BTB/POZ and T1‑type BTB domain annotations align with the literature (BTB/POZ/T1 oligomerization module; H1 module for Gβγ engagement in paralogs) (https://doi.org/10.1073/pnas.1903024116; https://doi.org/10.1038/s41586-019-0990-0) (zuo2019structuralbasisfor pages 1-1, zheng2019structuralbasisfor pages 1-2, zuo2019structuralbasisfor pages 7-7, zheng2019structuralbasisfor pages 2-4).
- Functional class: KCTD16 is an auxiliary subunit of metabotropic GABAB receptors (GBRs). Native GBR complexes comprise principal subunits GABAB1 and GABAB2 plus auxiliary KCTDs (notably KCTD8, KCTD12/12b, KCTD16). KCTD16 modulates GBR signaling kinetics and amplitude, particularly in coupling to G protein-gated inwardly rectifying K+ channels (GIRK) (https://doi.org/10.1073/pnas.1903024116; https://doi.org/10.1038/s41586-019-0990-0) (zuo2019structuralbasisfor pages 1-1, zheng2019structuralbasisfor pages 1-2).

2) Mechanism, interactions, pathways, and localization
- Direct molecular interfaces and stoichiometry: The KCTD16 BTB/T1 domain forms an open pentamer that wraps around one copy of the GABAB2 C-terminal peptide, establishing a 1:5 GB2 peptide:KCTD16 stoichiometry. Key interfacial residues include KCTD16 Q34, F80, P101, E102 and GABAB2 I898, Y903, L904; mutating these residues disrupts both biochemical association and functional modulation of GBR→GIRK currents (https://doi.org/10.1073/pnas.1903024116) (zuo2019structuralbasisfor pages 1-3, zuo2019structuralbasisfor pages 7-7, zuo2019structuralbasisfor pages 9-10).
- H1–Gβγ engagement and desensitization paradigm: KCTD family H1 domains can oligomerize to bind multiple Gβγ heterodimers cooperatively in a 5:5 complex, enabling rapid desensitization of GBR→GIRK signaling by stripping Gβγ from GIRK after initial activation. Quantitative measures for KCTD12 show H1–Gβγ KD ~185 nM and cooperative 5:5 assembly; analogous architecture and receptor tethering is proposed to underlie KCTD effects broadly, including KCTD16 (https://doi.org/10.1038/s41586-019-0990-0) (zheng2019structuralbasisfor pages 2-4, zheng2019structuralbasisfor pages 12-16).
- Kinetic specialization among KCTDs: KCTD12/12b enforce rapid desensitization of GABAB‑evoked GIRK currents by Gβγ sequestration, whereas KCTD8 and KCTD16 generally confer primarily non‑desensitizing/sustained responses; KCTD8/16 possess additional C‑terminal features (including H2) that oppose desensitization (https://doi.org/10.1073/pnas.1903024116) (zuo2019structuralbasisfor pages 1-3, zuo2019structuralbasisfor pages 1-1).
- Pathway context: KCTD16 operates within the canonical GBR pathway (GABAB→Gi/o→Gβγ→GIRK; and presynaptically Gβγ→VGCC inhibition), shaping postsynaptic inhibitory K+ currents and presynaptic release probability. Allosteric and G protein readouts show KCTD-dependent modulation of G protein conformations and cAMP pathway efficacy across KCTD paralogs; KCTD8/12/16 redundantly sustain the efficacy of inhibitory GPCR signals to cAMP in neurons (https://doi.org/10.1016/j.neuropharm.2014.08.020; https://doi.org/10.1073/pnas.2119237119) (rajalu2015pharmacologicalcharacterizationof pages 5-7, muntean2022membersofthe pages 3-5).
- Subcellular localization and brain distribution: In mouse brain, KCTD16 mRNA and protein are broadly expressed with prominent enrichment across thalamic nuclei, hippocampal CA1, dentate gyrus (somata/neuropil bands), amygdala (lateral and basolateral nuclei), olfactory regions, claustrum, and septum. In the adult thalamus, GABAB receptors predominantly incorporate KCTD16 based on subtype distributions. Immunolocalization shows KCTD16 at granule cell somata and neuropil in dentate gyrus and colocalization with GABAB2 in specific layers, supporting a postsynaptic role, with additional presence in interneuron-rich layers (https://doi.org/10.1002/cne.22610) (metz2011distributionofthe pages 7-10).

3) Recent developments and latest research (prioritizing 2023–2024)
- GPCR regulation reviews: Recent Trends in Neurosciences review emphasizes constitutive binding of KCTD16 (and KCTD8/12) to GABAB2 C‑terminus as a paradigm for auxiliary control of neuromodulatory GPCRs and highlights diverse GPCR–GPCR crosstalk and effector competition (2024; https://doi.org/10.1016/j.tins.2024.05.008) (gonzalezhernandez2024emergingmodesof pages 7-9).
- KCTD–Cullin3 recognition landscape: A 2024 IJMS structural analysis using AlphaFold indicates that KCTD subcluster harboring GABAB-binding proteins (including KCTD16) shows no structural propensity for Cul3 binding via BTB, in contrast to other KCTDs that serve as Cul3 adaptors. This suggests that KCTD16’s BTB evolved primarily to assemble GBR complexes rather than Cul3 E3 ligase scaffolds (2024; https://doi.org/10.3390/ijms25031881) (balasco2024acomprehensiveanalysis pages 8-9).
- Proteomic context at synapses: A 2023 cerebellar proteomics study cataloging mGlu1 interactomes discussed KCTD family members as part of synaptic protein networks, highlighting complex, region‑specific assemblies and the possibility of indirect cross‑complex interactions in native tissue (2023; https://doi.org/10.3390/cells12091325) (mansouri2023proteinnetworksassociated pages 13-15).
- System-level physiology: A 2023 review of GABAB signaling in auditory circuits details presynaptic and postsynaptic mechanisms (GIRK, VGCC) and plasticity that are shaped by GBR auxiliary components, consistent with regional roles where KCTD16 is enriched (2023; https://doi.org/10.3389/fendo.2023.1195038) (turecek2023theroleof pages 6-7).

4) Current applications and real-world implementations
- Structural biology and mechanistic dissection: KCTD16 has enabled high-resolution determination of the GBR–auxiliary subunit interface and underpins mechanistic models for temporal control of GIRK signaling; these coordinates and models are used to guide mutational and pharmacological experiments (2019; PDB 6OCP; https://doi.org/10.1073/pnas.1903024116; 2019; https://doi.org/10.1038/s41586-019-0990-0) (zuo2019structuralbasisfor pages 1-1, zuo2019structuralbasisfor pages 9-10, zheng2019structuralbasisfor pages 2-4, zheng2019structuralbasisfor pages 12-16).
- Electrophysiology and pharmacology: Heterologous and neuronal systems employ KCTD16 co-expression to measure baclofen-evoked GIRK currents, kinetic modulation, and G protein conformational BRET assays, often comparing with KCTD8/12/12b to parse desensitization versus sustained responses (2015; https://doi.org/10.1016/j.neuropharm.2014.08.020) (rajalu2015pharmacologicalcharacterizationof pages 5-7).
- Clinical diagnostics: Incorporation of KCTD16 into GABABR cell-based assays increases sensitivity of autoantibody detection for anti-GABABR encephalitis without loss of specificity, aiding earlier diagnosis and tumor screening (2019; https://doi.org/10.1093/brain/awz094) (coevordenhameete2019theexpandedclinical pages 1-2).

5) Expert opinions and analysis from authoritative sources
- Structural consensus: Nature and PNAS structural studies converge on a bipartite mechanism: BTB/T1 mediates a 1:5 tethering of KCTD to GABAB2, while H1 pentamers engage multiple Gβγ to sculpt signal kinetics; cooperative Gβγ engagement explains rapid desensitization in KCTD12 and the more sustained modulation seen for KCTD16 lacking the canonical desensitization motif (2019; https://doi.org/10.1038/s41586-019-0990-0; https://doi.org/10.1073/pnas.1903024116) (zheng2019structuralbasisfor pages 2-4, zheng2019structuralbasisfor pages 1-2, zuo2019structuralbasisfor pages 1-3).
- Family-level specialization: 2024 IJMS analysis suggests that the GABAB‑binding KCTD clade (including KCTD16) does not structurally favor Cul3 binding, reinforcing the view that not all BTB-containing KCTDs are ubiquitin ligase adaptors; instead, KCTD16’s BTB is specialized for receptor complex assembly (2024; https://doi.org/10.3390/ijms25031881) (balasco2024acomprehensiveanalysis pages 8-9).
- Systems neuroscience perspective: 2024 Trends review frames KCTD16 as a key determinant of synaptic GPCR signaling nanoscale organization and crosstalk restraint, through constitutive receptor association and effector competition paradigms in neurons (2024; https://doi.org/10.1016/j.tins.2024.05.008) (gonzalezhernandez2024emergingmodesof pages 7-9).

6) Relevant statistics and data from recent studies
- Structural stoichiometry: 1 GABAB2 C‑terminal peptide per KCTD16 BTB/T1 pentamer (1:5), supported by crystal structure (PDB 6OCP) and mutational validation (2019; https://doi.org/10.1073/pnas.1903024116) (zuo2019structuralbasisfor pages 1-3, zuo2019structuralbasisfor pages 9-10).
- Gβγ binding/desensitization parameters (family paradigm): KCTD12 H1–Gβγ KD ~185 nM; cooperative assembly into 5:5 complexes; H1 mutants (R232D/R257D) abolish Gβγ binding and prevent desensitization (2019; https://doi.org/10.1038/s41586-019-0990-0) (zheng2019structuralbasisfor pages 2-4, zheng2019structuralbasisfor pages 12-16).
- Brain distribution: In adult mouse thalamus, KCTD16 is highly expressed across many nuclei, supporting the inference that many thalamic GBRs incorporate KCTD16; hippocampal CA1 enrichment and dentate gyrus somatic/neuropil labeling are prominent (2011; https://doi.org/10.1002/cne.22610) (metz2011distributionofthe pages 7-10).
- Clinical autoantibodies: In a cohort of 32 anti‑GABABR encephalitis patients, KCTD16 autoantibodies were present in 23/32; tumor association was 18/19 (95%) in KCTD16‑Ab+ vs 3/9 (33%) in KCTD16‑Ab− (P = 0.001). Adding KCTD16 to the GABABR cell-based assay increased sensitivity without loss of specificity (2019; https://doi.org/10.1093/brain/awz094) (coevordenhameete2019theexpandedclinical pages 1-2).

7) Subcellular site of action and role in defined signaling circuits
- Postsynaptic inhibition: By tethering to GABAB2 and shaping Gβγ availability and GIRK channel interactions, KCTD16 contributes to the amplitude and temporal profile of postsynaptic inhibitory currents, particularly in dendritic compartments where GABABRs are enriched (https://doi.org/10.1073/pnas.1903024116; https://doi.org/10.1002/cne.22610) (zuo2019structuralbasisfor pages 1-1, metz2011distributionofthe pages 7-10).
- Presynaptic modulation: Within the GBR→Gi/o framework, KCTD16-containing complexes likely modulate presynaptic Gβγ signaling to VGCCs and release probability in regions where it is abundant, consistent with physiological reviews of auditory pathways (2023; https://doi.org/10.3389/fendo.2023.1195038) (turecek2023theroleof pages 6-7).

Key evidence summary table
| Category | Key finding | Primary source (journal) | Year | URL |
|---|---|---:|---:|---|
| Identity & domains | KCTD16 is a BTB/POZ-containing KCTD family protein with an N-terminal T1/BTB oligomerization domain and C‑terminal H1 (and H2) homology regions; the T1/BTB mediates pentamer formation. (zuo2019structuralbasisfor pages 1-1, zheng2019structuralbasisfor pages 1-2) | PNAS | 2019 | https://doi.org/10.1073/pnas.1903024116 |
| Primary function | Functions as an auxiliary subunit of neuronal GABAB receptors, modulating receptor expression and the amplitude/kinetics of GIRK-mediated K+ currents. (zuo2019structuralbasisfor pages 1-1, zheng2019structuralbasisfor pages 1-2) | PNAS | 2019 | https://doi.org/10.1073/pnas.1903024116 |
| Structural mechanism — T1/BTB | The KCTD16 T1/BTB domain forms an open pentamer that binds one GABAB2 C‑terminal peptide (1:5 stoichiometry; structure deposited PDB 6OCP); interfacial residues (e.g., F80, Q34) are required for binding. (zuo2019structuralbasisfor pages 1-1, zuo2019structuralbasisfor pages 9-10) | PNAS | 2019 | https://doi.org/10.1073/pnas.1903024116 |
| Structural mechanism — H1/Gβγ | KCTD family H1 domains assemble symmetrically to engage multiple Gβγ subunits cooperatively (5:5 assemblies demonstrated for KCTD12), a mechanism proposed to strip Gβγ from GIRK and drive desensitization. (zheng2019structuralbasisfor pages 1-2, zheng2019structuralbasisfor pages 2-4) | Nature | 2019 | https://doi.org/10.1038/s41586-019-0990-0 |
| Key interaction partners | Direct/functional partners include the GABAB2 C‑terminal tail, Gβγ heterodimers, and GIRK channels; mutations at the interfaces disrupt biochemical binding and GIRK modulation. (zheng2019structuralbasisfor pages 1-2, zuo2019structuralbasisfor pages 1-1, zuo2019structuralbasisfor pages 9-10) | Nature / PNAS | 2019 | https://doi.org/10.1038/s41586-019-0990-0 |
| Signaling pathway context | Operates within the GABAB → Gi/o → Gβγ → GIRK signaling axis, thereby affecting postsynaptic inhibition and presynaptic release probability; KCTDs also modulate downstream GPCR/G-protein readouts in pharmacological assays. (zheng2019structuralbasisfor pages 1-2, rajalu2015pharmacologicalcharacterizationof pages 5-7, muntean2022membersofthe pages 3-5) | Neuropharmacology / Nature / PNAS | 2015 / 2019 / 2022 | https://doi.org/10.1016/j.neuropharm.2014.08.020 |
| Kinetic effects vs other KCTDs | KCTD12/12b contain H1 motifs that produce rapid desensitization (uncoupling Gβγ from GIRK); by contrast KCTD8 and KCTD16 typically produce primarily non‑desensitizing or sustained GABAB‑GIRK responses. (zuo2019structuralbasisfor pages 9-10, zuo2019structuralbasisfor pages 1-1) | PNAS / Neuropharmacology | 2019 / 2015 | https://doi.org/10.1073/pnas.1903024116 |
| Brain distribution / localization | In mouse brain KCTD16 shows high expression across thalamic nuclei and is enriched in hippocampal CA1, amygdala (lateral/basolateral nuclei) and dentate regions; localization can be somatic/neuropil and region‑specific. (metz2011distributionofthe pages 7-10, turecek2023theroleof pages 6-7) | Journal of Comparative Neurology | 2011 | https://doi.org/10.1002/cne.22610 |
| Clinical relevance — autoantibodies | KCTD16 autoantibodies were detected in 23/32 patients with anti‑GABABR encephalitis; KCTD16 Ab positivity strongly associated with an underlying tumour (18/19 with KCTD16 Abs vs 3/9 without; P = 0.001). (coevordenhameete2019theexpandedclinical pages 1-2) | Brain | 2019 | https://doi.org/10.1093/brain/awz094 |
| Diagnostic utility | Adding KCTD16 to GABABR cell‑based assays increased assay sensitivity for anti‑GABABR encephalitis detection without loss of specificity. (coevordenhameete2019theexpandedclinical pages 1-2) | Brain | 2019 | https://doi.org/10.1093/brain/awz094 |
| Recent developments (2023–2024) | Recent reviews/analyses (Trends, IJMS, Cells) highlight KCTD16's constitutive GABAB2 binding, roles in GPCR regulatory networks and family‑level analyses of Cullin3 partnerships that inform potential ubiquitin‑ligase adapter roles across KCTDs. (gonzalezhernandez2024emergingmodesof pages 7-9, balasco2024acomprehensiveanalysis pages 8-9, mansouri2023proteinnetworksassociated pages 13-15) | Trends in Neurosciences / Int. J. Mol. Sci. / Cells | 2024 / 2024 / 2023 | https://doi.org/10.1016/j.tins.2024.05.008 |
| Applications in research | KCTD16 has been used in high‑resolution structural studies (X‑ray/cryo‑EM), electrophysiology (baclofen‑evoked GIRK assays), proteomics and diagnostic assay development for GABAB complexes and encephalitis biomarker work. (zuo2019structuralbasisfor pages 1-1, zheng2019structuralbasisfor pages 1-2, mansouri2023proteinnetworksassociated pages 13-15) | PNAS / Nature / Cells | 2019 / 2019 / 2023 | https://doi.org/10.1073/pnas.1903024116 |


*Table: Compact, cited summary of major, evidence-backed facts on human KCTD16 (UniProt Q68DU8), covering identity, structure, partners, signaling role, brain distribution, kinetics vs other KCTDs, clinical autoantibody data, and recent (2023–2024) analyses; useful as a quick reference for research and diagnostics.*

Ambiguity check and scope note
- Ambiguity: The symbol “KCTD16” is used consistently in human studies and in mouse distribution studies; no conflicting gene/protein with this symbol was encountered in other organisms within the cited corpus. The functional and structural claims here are specific to Homo sapiens KCTD16 or to conserved mammalian orthologs where explicitly noted (zuo2019structuralbasisfor pages 1-1, zheng2019structuralbasisfor pages 1-2, metz2011distributionofthe pages 7-10).
- Family/function inference boundaries: While many KCTDs can act as Cul3 adaptors, 2024 modeling suggests the GABAB-binding clade (including KCTD16) does not engage Cul3 via BTB, cautioning against overgeneralization of ubiquitin E3 adaptor roles to KCTD16 (https://doi.org/10.3390/ijms25031881) (balasco2024acomprehensiveanalysis pages 8-9).

References (URLs and dates)
- Zuo et al., PNAS 2019. Structural basis for auxiliary subunit KCTD16 regulation of the GABAB receptor. Published Apr 2019. URL: https://doi.org/10.1073/pnas.1903024116 (zuo2019structuralbasisfor pages 1-1, zuo2019structuralbasisfor pages 1-3, zuo2019structuralbasisfor pages 7-7, zuo2019structuralbasisfor pages 9-10).
- Zheng et al., Nature 2019. Structural basis for KCTD-mediated rapid desensitization of GABAB signalling. Published Feb 2019. URL: https://doi.org/10.1038/s41586-019-0990-0 (zheng2019structuralbasisfor pages 2-4, zheng2019structuralbasisfor pages 12-16, zheng2019structuralbasisfor pages 1-2, zheng2019structuralbasisfor pages 18-22).
- Metz et al., J Comp Neurol 2011. Distribution of the auxiliary GABAB receptor subunits KCTD8, 12, 12b, and 16 in the mouse brain. Published Jun 2011. URL: https://doi.org/10.1002/cne.22610 (metz2011distributionofthe pages 7-10).
- Rajalu et al., Neuropharmacology 2015. Pharmacological characterization of GABAB receptor subtypes assembled with auxiliary KCTD subunits. Published Jan 2015. URL: https://doi.org/10.1016/j.neuropharm.2014.08.020 (rajalu2015pharmacologicalcharacterizationof pages 5-7).
- van Coevorden‑Hameete et al., Brain 2019. The expanded clinical spectrum of anti‑GABABR encephalitis and added value of KCTD16 autoantibodies. Advance Access Apr 22, 2019. URL: https://doi.org/10.1093/brain/awz094 (coevordenhameete2019theexpandedclinical pages 1-2).
- Tureček et al., Frontiers in Endocrinology 2023. The role of GABAB receptors in the subcortical pathways of the mammalian auditory system. Published Aug 2023. URL: https://doi.org/10.3389/fendo.2023.1195038 (turecek2023theroleof pages 6-7).
- Gonzalez‑Hernandez et al., Trends in Neurosciences 2024. Emerging modes of regulation of neuromodulatory GPCRs. Published Aug 2024. URL: https://doi.org/10.1016/j.tins.2024.05.008 (gonzalezhernandez2024emergingmodesof pages 7-9).
- Balasco et al., International Journal of Molecular Sciences 2024. A Comprehensive Analysis of the Structural Recognition between KCTD Proteins and Cullin 3. Published Feb 2024. URL: https://doi.org/10.3390/ijms25031881 (balasco2024acomprehensiveanalysis pages 8-9).
- Muntean et al., PNAS 2022. Members of the KCTD family are major regulators of cAMP signaling. Published Dec 2022. URL: https://doi.org/10.1073/pnas.2119237119 (muntean2022membersofthe pages 3-5).

Conclusion
Human KCTD16 is a BTB/POZ-domain auxiliary protein that constitutively associates with the GABAB2 C‑terminus in a 1:5 pentameric arrangement and sculpts GABAB→Gβγ→GIRK signaling kinetics. In contrast to KCTD12, KCTD16 generally supports sustained responses, consistent with differences in C‑terminal modules. Regionally enriched expression, particularly in thalamus and hippocampus, implies substantial roles in synaptic inhibition and plasticity. Clinically, KCTD16 autoantibodies are prevalent in anti‑GABABR encephalitis and improve diagnostic sensitivity, strongly flagging paraneoplastic etiologies. Recent (2023–2024) analyses refine KCTD16’s place within GPCR regulatory networks and suggest its BTB domain specializes in receptor complex assembly rather than Cul3 ligase scaffolding (zuo2019structuralbasisfor pages 1-1, zuo2019structuralbasisfor pages 1-3, zheng2019structuralbasisfor pages 2-4, metz2011distributionofthe pages 7-10, coevordenhameete2019theexpandedclinical pages 1-2, gonzalezhernandez2024emergingmodesof pages 7-9, balasco2024acomprehensiveanalysis pages 8-9).

References

1. (zuo2019structuralbasisfor pages 1-1): Hao Zuo, Ian Glaaser, Yulin Zhao, Igor Kurinov, Lidia Mosyak, Haonan Wang, Jonathan Liu, Jinseo Park, Aurel Frangaj, Emmanuel Sturchler, Ming Zhou, Patricia McDonald, Yong Geng, Paul A. Slesinger, and Qing R. Fan. Structural basis for auxiliary subunit kctd16 regulation of the gabab receptor. Proceedings of the National Academy of Sciences, 116:8370-8379, Apr 2019. URL: https://doi.org/10.1073/pnas.1903024116, doi:10.1073/pnas.1903024116. This article has 54 citations and is from a highest quality peer-reviewed journal.

2. (zheng2019structuralbasisfor pages 1-2): Sanduo Zheng, Nohely Abreu, Joshua Levitz, and Andrew C. Kruse. Structural basis for kctd-mediated rapid desensitization of gabab signalling. Nature, 567:127-131, Feb 2019. URL: https://doi.org/10.1038/s41586-019-0990-0, doi:10.1038/s41586-019-0990-0. This article has 97 citations and is from a highest quality peer-reviewed journal.

3. (zuo2019structuralbasisfor pages 7-7): Hao Zuo, Ian Glaaser, Yulin Zhao, Igor Kurinov, Lidia Mosyak, Haonan Wang, Jonathan Liu, Jinseo Park, Aurel Frangaj, Emmanuel Sturchler, Ming Zhou, Patricia McDonald, Yong Geng, Paul A. Slesinger, and Qing R. Fan. Structural basis for auxiliary subunit kctd16 regulation of the gabab receptor. Proceedings of the National Academy of Sciences, 116:8370-8379, Apr 2019. URL: https://doi.org/10.1073/pnas.1903024116, doi:10.1073/pnas.1903024116. This article has 54 citations and is from a highest quality peer-reviewed journal.

4. (zheng2019structuralbasisfor pages 2-4): Sanduo Zheng, Nohely Abreu, Joshua Levitz, and Andrew C. Kruse. Structural basis for kctd-mediated rapid desensitization of gabab signalling. Nature, 567:127-131, Feb 2019. URL: https://doi.org/10.1038/s41586-019-0990-0, doi:10.1038/s41586-019-0990-0. This article has 97 citations and is from a highest quality peer-reviewed journal.

5. (zuo2019structuralbasisfor pages 1-3): Hao Zuo, Ian Glaaser, Yulin Zhao, Igor Kurinov, Lidia Mosyak, Haonan Wang, Jonathan Liu, Jinseo Park, Aurel Frangaj, Emmanuel Sturchler, Ming Zhou, Patricia McDonald, Yong Geng, Paul A. Slesinger, and Qing R. Fan. Structural basis for auxiliary subunit kctd16 regulation of the gabab receptor. Proceedings of the National Academy of Sciences, 116:8370-8379, Apr 2019. URL: https://doi.org/10.1073/pnas.1903024116, doi:10.1073/pnas.1903024116. This article has 54 citations and is from a highest quality peer-reviewed journal.

6. (zuo2019structuralbasisfor pages 9-10): Hao Zuo, Ian Glaaser, Yulin Zhao, Igor Kurinov, Lidia Mosyak, Haonan Wang, Jonathan Liu, Jinseo Park, Aurel Frangaj, Emmanuel Sturchler, Ming Zhou, Patricia McDonald, Yong Geng, Paul A. Slesinger, and Qing R. Fan. Structural basis for auxiliary subunit kctd16 regulation of the gabab receptor. Proceedings of the National Academy of Sciences, 116:8370-8379, Apr 2019. URL: https://doi.org/10.1073/pnas.1903024116, doi:10.1073/pnas.1903024116. This article has 54 citations and is from a highest quality peer-reviewed journal.

7. (zheng2019structuralbasisfor pages 12-16): Sanduo Zheng, Nohely Abreu, Joshua Levitz, and Andrew C. Kruse. Structural basis for kctd-mediated rapid desensitization of gabab signalling. Nature, 567:127-131, Feb 2019. URL: https://doi.org/10.1038/s41586-019-0990-0, doi:10.1038/s41586-019-0990-0. This article has 97 citations and is from a highest quality peer-reviewed journal.

8. (rajalu2015pharmacologicalcharacterizationof pages 5-7): Mathieu Rajalu, Thorsten Fritzius, Lisa Adelfinger, Valerie Jacquier, Valerie Besseyrias, Martin Gassmann, and Bernhard Bettler. Pharmacological characterization of gabab receptor subtypes assembled with auxiliary kctd subunits. Neuropharmacology, 88:145-154, Jan 2015. URL: https://doi.org/10.1016/j.neuropharm.2014.08.020, doi:10.1016/j.neuropharm.2014.08.020. This article has 45 citations and is from a highest quality peer-reviewed journal.

9. (muntean2022membersofthe pages 3-5): Brian S. Muntean, Subhi Marwari, Xiaona Li, Douglas C. Sloan, Brian D. Young, James A. Wohlschlegel, and Kirill A. Martemyanov. Members of the kctd family are major regulators of camp signaling. Proceedings of the National Academy of Sciences of the United States of America, Dec 2022. URL: https://doi.org/10.1073/pnas.2119237119, doi:10.1073/pnas.2119237119. This article has 36 citations and is from a highest quality peer-reviewed journal.

10. (metz2011distributionofthe pages 7-10): Michaela Metz, Martin Gassmann, Bernd Fakler, Nicole Schaeren‐Wiemers, and Bernhard Bettler. Distribution of the auxiliary gabab receptor subunits kctd8, 12, 12b, and 16 in the mouse brain. Journal of Comparative Neurology, 519:1435-1454, Jun 2011. URL: https://doi.org/10.1002/cne.22610, doi:10.1002/cne.22610. This article has 100 citations and is from a peer-reviewed journal.

11. (gonzalezhernandez2024emergingmodesof pages 7-9): Alberto J. Gonzalez-Hernandez, Hermany Munguba, and Joshua Levitz. Emerging modes of regulation of neuromodulatory g protein-coupled receptors. Trends in Neurosciences, 47:635-650, Aug 2024. URL: https://doi.org/10.1016/j.tins.2024.05.008, doi:10.1016/j.tins.2024.05.008. This article has 23 citations and is from a highest quality peer-reviewed journal.

12. (balasco2024acomprehensiveanalysis pages 8-9): Nicole Balasco, Luciana Esposito, Giovanni Smaldone, Marco Salvatore, and Luigi Vitagliano. A comprehensive analysis of the structural recognition between kctd proteins and cullin 3. International Journal of Molecular Sciences, 25:1881, Feb 2024. URL: https://doi.org/10.3390/ijms25031881, doi:10.3390/ijms25031881. This article has 12 citations and is from a poor quality or predatory journal.

13. (mansouri2023proteinnetworksassociated pages 13-15): Mahnaz Mansouri, Leopold Kremser, Thanh-Phuong Nguyen, Yu Kasugai, Laura Caberlotto, Martin Gassmann, Bettina Sarg, Herbert Lindner, Bernhard Bettler, Lucia Carboni, and Francesco Ferraguti. Protein networks associated with native metabotropic glutamate 1 receptors (mglu1) in the mouse cerebellum. Cells, 12:1325, May 2023. URL: https://doi.org/10.3390/cells12091325, doi:10.3390/cells12091325. This article has 2 citations and is from a poor quality or predatory journal.

14. (turecek2023theroleof pages 6-7): Rostislav Tureček, Adolf Melichar, Michaela Králíková, and Bohdana Hrušková. The role of gabab receptors in the subcortical pathways of the mammalian auditory system. Frontiers in Endocrinology, Aug 2023. URL: https://doi.org/10.3389/fendo.2023.1195038, doi:10.3389/fendo.2023.1195038. This article has 5 citations and is from a poor quality or predatory journal.

15. (coevordenhameete2019theexpandedclinical pages 1-2): Marleen H van Coevorden-Hameete, Marienke A A M de Bruijn, Esther de Graaff, Danielle A E M Bastiaansen, Marco W J Schreurs, Jeroen A A Demmers, Melanie Ramberger, Esther S P Hulsenboom, Mariska M P Nagtzaam, Sanae Boukhrissi, Jan H Veldink, Jan J G M Verschuuren, Casper C Hoogenraad, Peter A E Sillevis Smitt, and Maarten J Titulaer. The expanded clinical spectrum of anti-gababr encephalitis and added value of kctd16 autoantibodies. Brain, 142:1631-1643, Apr 2019. URL: https://doi.org/10.1093/brain/awz094, doi:10.1093/brain/awz094. This article has 105 citations and is from a highest quality peer-reviewed journal.

16. (zheng2019structuralbasisfor pages 18-22): Sanduo Zheng, Nohely Abreu, Joshua Levitz, and Andrew C. Kruse. Structural basis for kctd-mediated rapid desensitization of gabab signalling. Nature, 567:127-131, Feb 2019. URL: https://doi.org/10.1038/s41586-019-0990-0, doi:10.1038/s41586-019-0990-0. This article has 97 citations and is from a highest quality peer-reviewed journal.

## Citations

1. metz2011distributionofthe pages 7-10
2. gonzalezhernandez2024emergingmodesof pages 7-9
3. balasco2024acomprehensiveanalysis pages 8-9
4. mansouri2023proteinnetworksassociated pages 13-15
5. turecek2023theroleof pages 6-7
6. rajalu2015pharmacologicalcharacterizationof pages 5-7
7. coevordenhameete2019theexpandedclinical pages 1-2
8. muntean2022membersofthe pages 3-5
9. zuo2019structuralbasisfor pages 1-1
10. zheng2019structuralbasisfor pages 1-2
11. zuo2019structuralbasisfor pages 7-7
12. zheng2019structuralbasisfor pages 2-4
13. zuo2019structuralbasisfor pages 1-3
14. zuo2019structuralbasisfor pages 9-10
15. zheng2019structuralbasisfor pages 12-16
16. zheng2019structuralbasisfor pages 18-22
17. https://doi.org/10.1073/pnas.1903024116;
18. https://doi.org/10.1038/s41586-019-0990-0
19. https://doi.org/10.1073/pnas.1903024116
20. https://doi.org/10.1016/j.neuropharm.2014.08.020;
21. https://doi.org/10.1073/pnas.2119237119
22. https://doi.org/10.1002/cne.22610
23. https://doi.org/10.1016/j.tins.2024.05.008
24. https://doi.org/10.3390/ijms25031881
25. https://doi.org/10.3390/cells12091325
26. https://doi.org/10.3389/fendo.2023.1195038
27. https://doi.org/10.1016/j.neuropharm.2014.08.020
28. https://doi.org/10.1093/brain/awz094
29. https://doi.org/10.1038/s41586-019-0990-0;
30. https://doi.org/10.1073/pnas.1903024116,
31. https://doi.org/10.1038/s41586-019-0990-0,
32. https://doi.org/10.1016/j.neuropharm.2014.08.020,
33. https://doi.org/10.1073/pnas.2119237119,
34. https://doi.org/10.1002/cne.22610,
35. https://doi.org/10.1016/j.tins.2024.05.008,
36. https://doi.org/10.3390/ijms25031881,
37. https://doi.org/10.3390/cells12091325,
38. https://doi.org/10.3389/fendo.2023.1195038,
39. https://doi.org/10.1093/brain/awz094,